找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Immunotherapy for Gastrointestinal Malignancies; Ramakrishna Vadde,Ganji Purnachandra Nagaraju Book 2020 The Editor(s) (if applicable) and

[復(fù)制鏈接]
樓主: 驅(qū)逐
31#
發(fā)表于 2025-3-27 00:01:48 | 只看該作者
32#
發(fā)表于 2025-3-27 04:23:02 | 只看該作者
Tumor Heterogeneity: Challenges and Perspectives for Gastrointestinal Cancer Therapy,son for the low treatment response rate in cancer patients. Thus, there is always a quest to understand the tumor heterogeneity in any cancer type. In this chapter, the authors attempted to understand the types and drivers for tumor heterogeneity, especially in gastrointestinal cancers, and discusse
33#
發(fā)表于 2025-3-27 05:35:34 | 只看該作者
Immunocomposition of Gastrointestinal Tract of Gut,rwhelming load of antigens in the form of dietary antigens on a daily basis. The GI tract has played dual role in the body, in that it performs uptake of nutrients and digestion while also performing out the complex and principal task of maintaining immune homeostasis, i.e., maintaining the balance
34#
發(fā)表于 2025-3-27 11:43:56 | 只看該作者
35#
發(fā)表于 2025-3-27 16:05:21 | 只看該作者
36#
發(fā)表于 2025-3-27 19:34:49 | 只看該作者
Immune Cell Therapy Against Gastrointestinal Tract Cancers, the healthcare sector across the globe. Recently advancements in high throughput techniques provide us with a unique opportunity to detect biomarkers and treat various diseases, including GI cancer, more comprehensively. However, most of these approaches are ineffective for treating patients with a
37#
發(fā)表于 2025-3-28 01:23:56 | 只看該作者
Immune Checkpoint Inhibitors in Gastrointestinal Malignancies,se of cancer related deaths. GI cancers are treated by surgery, radiotherapy, and chemotherapy. The overall survival rate (5 years of survival) after the surgery is very poor in patients with GI cancers. To increase the survival rate adjuvant therapies like chemotherapy and radiotherapy were perform
38#
發(fā)表于 2025-3-28 05:57:20 | 只看該作者
39#
發(fā)表于 2025-3-28 06:33:32 | 只看該作者
40#
發(fā)表于 2025-3-28 11:12:25 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 22:05
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
富顺县| 贺州市| 米泉市| 桐梓县| 那坡县| 彰化市| 青岛市| 富顺县| 三穗县| 祥云县| 会泽县| 界首市| 汽车| 呼图壁县| 湄潭县| 荣昌县| 东台市| 岐山县| 岳阳县| 张家口市| 宁南县| 淮阳县| 永济市| 绿春县| 新余市| 都兰县| 金寨县| 波密县| 梅州市| 甘肃省| 林西县| 齐河县| 磐安县| 济源市| 六盘水市| 东山县| 洛浦县| 慈溪市| 邹城市| 铜梁县| 翁源县|